title: Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension.
abstract: To evaluate the acute BP response to iv fenoldopam mesylate (FNP), 14 patients with severe hypertension (diastolic BP 120 to 170 mm Hg) were studied in an open-label trial. Initial infusion rate of FNP was 0.1 microgram/kg.min. Titration to diastolic BP goal (95 to 110 mm Hg) was followed by a constant infusion phase (greater than or equal to 6 h), a detitration phase (2 h), and a postinfusion phase. FNP reduced BP by 27/29 mm Hg (p less than .001) with no significant effect on heart rate. Maintenance of the BP effect was noted through the 6 h of constant rate infusion. Mild, transient vasodilating-associated adverse effects were noted with FNP. We conclude that FNP is an effective, well-tolerated iv antihypertensive agent for acute BP reduction in a severely hypertensive population.
authors.affiliation: Department of Medicine, Case Western Reserve University, Cleveland, OH.
authors.forename: M A
authors.initials: MA
authors.lastname: Munger
authors.forename: W F
authors.initials: WF
authors.lastname: Rutherford
authors.forename: L
authors.initials: L
authors.lastname: Anderson
authors.forename: A I
authors.initials: AI
authors.lastname: Hakki
authors.forename: F M
authors.initials: FM
authors.lastname: Gonzalez
authors.forename: E M
authors.initials: EM
authors.lastname: Bednarczyk
authors.forename: G
authors.initials: G
authors.lastname: Emmanuel
authors.forename: S G
authors.initials: SG
authors.lastname: Weed
authors.forename: E A
authors.initials: EA
authors.lastname: Panacek
authors.forename: J A
authors.initials: JA
authors.lastname: Green
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D018818:Fenoldopam; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D014665:Vasodilator Agents; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D018818:Fenoldopam